Pharmaceutical Drugs Coverage

Complete Nutrition Products Market Definition

Complete nutrition products refer to a diverse range of dietary supplements and meal replacements designed to provide a balanced mix of essential nutrients. These products are formulated to support various dietary needs and lifestyle choices, offering a convenient solution for individuals seeking nutritious, balanced meals on the go. The complete nutrition products market consists of sales, by entities (organizations, sole traders or partnerships), of complete nutrition products that are used by a broad spectrum of consumers, including infants, children, adults and the elderly, each with unique nutritional requirements and preferences.

Anesthetics Market Definition

Anesthetics encompass a diverse range of substances or drugs, utilized to induce a temporary loss of sensation or consciousness in individuals undergoing medical procedures, surgery or other interventions. These substances play a crucial role in managing pain, facilitating medical procedures and ensuring patient comfort during various medical procedures. The anesthetics market consists of sales of anesthetics products by entities (organizations, sole traders or partnerships) primarily engaged in the development, production and distribution of substances, agents or techniques used to induce anesthesia. These products find extensive applications in healthcare settings, including hospitals, clinics, ambulatory surgical centers and dental practices.

Automated Liquid Handling Systems Market Definition And Segments

Automated liquid handling systems refer to computerized devices that perform liquid transfers in laboratory settings. These systems utilize software to execute various protocols, offering precise sample preparation for high-throughput sequencing, screening, bioassays, and more. They can include components such as heating or cooling, shaking, and centrifugal force for contactless liquid removal. The main types of automated liquid handling systems are automated liquid handling systems and semi-automated liquid handling systems. Automated liquid handling systems are advanced machines designed to automate the process of pipetting liquids in laboratories, enhancing efficiency and accuracy. The various applications involved are drug discovery and ADME-tox research, cancer and genomic research, bioprocessing or biotechnology, and other applications, which are used by various end users such as contract research organizations, pharmaceutical and biotechnology, and academic and research institutes. The automated liquid handling systems market covered in this report is segmented – 1) By Type: Automated Liquid Handling System, Semi-automated Liquid Handling System 2) By Application: Drug Discovery And ADME-Tox Research, Cancer And Genomic Research, Bioprocessing Or Biotechnology, Other Applications 3) By End User: Contract Research Organizations, Pharmaceutical and Biotechnology, Academic and Research Institutes The automated liquid handling systems market size has grown strongly in recent years. It will grow from $3.65 billion in 2023 to $3.92 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to demand for high-throughput screening, growth in pharmaceutical and biotechnology industries, need for precision and accuracy in liquid handling, Increasing automation in laboratories, rising adoption of personalized medicine, expansion of drug discovery and development, cost and time efficiency. The automated liquid handling systems market size is expected to see strong growth in the next few years. It will grow to $5.27 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the acceleration of drug discovery processes, expansion of research in genomics and proteomics, demand for high-throughput diagnostics, adoption in emerging markets, shift towards miniaturization, focus on improving reproducibility and data quality. Major trends in the forecast period include adoption of high-throughput systems, expansion in pharmaceutical industries, integration of robotic arms, development of miniaturized systems, collaboration between providers and laboratories, expansion in diagnostic laboratories, adoption of touchless technologies, and increasing emphasis on compliance.

Chronic Disease Surge Propels Automated Liquid Handling Market

The growing prevalence of chronic diseases is expected to propel the growth of the automated liquid handling systems market going forward. A chronic disease refers to a long-lasting condition that can be managed but typically cannot be cured completely. The growing prevalence of chronic diseases is due to increased consumption of processed foods, sedentary lifestyles characterized by prolonged sitting, and reduced physical activity. Automated liquid handling systems offer advantages such as improved accuracy, reproducibility, and throughput compared to manual pipetting, making them indispensable in the pharmaceutical and biotechnology industries. For instance, in January 2023, according to a report published by the National Institutes of Health (NIH), a US-based biomedical research agency, the number of people aged 50 and older with at least one chronic illness is predicted to rise by 99.5%, from 71.522 million in 2020 to 142.66 million in 2050. Additionally, in May 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency of the United States, in 2021, approximately 695,000 individuals in the United States succumbed to heart disease, equating to one out of every five deaths. Therefore, the growing prevalence of chronic disease is driving the growth of the automated liquid handling systems market. Major companies operating in the automated liquid handling systems market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Corning Inc., Agilent Technologies, Lonza, PerkinElmer Inc., Mettler-Toledo International Inc., Beckman Coulter, Waters Corp, Bio-Rad Laboratories Inc., Qiagen NV, Eppendorf AG, Tecan Group Ltd., Hamilton Company, Formulatrix Inc., Analytik Jena AG, LABCYTE Inc., Gilson Inc., BioTek Instruments Inc., Aurora Biomed Inc., Synchron Lab Automation, Hudson Robotics Inc., AUTOGEN Inc., Beijing TXTB

Advancements In Automated Liquid Handling

Companies operating in the automated liquid handling systems market are focused on developing dual-core pipetting technology solutions to strengthen their position in the market. Dual-core pipetting technology refers to a sophisticated liquid handling system used in laboratory settings for accurate and precise dispensing of liquids. For instance, in February 2022, SPT Labtech, a UK-based automated liquid handling manufacturer and designer, launched the apricot DC1 at SLAS 2022 in Boston. It is a compact 4-in-1 automated liquid handling platform controlled via software, enhancing various applications' throughput, standardization, and data quality. It consolidates four distinct pipetting instruments into one compact unit, facilitating high-volume and low-volume single- and multichannel pipetting tasks.

SPT Labtech Expands Liquid Handling Portfolio With Apricot Designs Acquisition

In February 2021, SPT Labtech, a UK-based manufacturer and designer of automated liquid handling acquired Apricot Designs for an undisclosed amount. Through the acquisition, SPT Labtech expanded its liquid handling technologies portfolio, enhancing its automation solutions for various scientific fields such as drug discovery, genomics, cryo-EM, sample management, and biobanking. Apricot Designs is a US-based company that designs and manufactures multichannel micro-volume pipettors, disposable pipette tips, and solid-phase extraction and liquid handling instruments. North America was the largest region in the automated liquid handling systems market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated liquid handling systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automated liquid handling systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The automated liquid handling systems market consists of sales of pipettes, consumables, software, and liquid handling workstations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The automated liquid handling systems market research report is one of a series of new reports from The Business Research Company that provides automated liquid handling systems market statistics, including the automated liquid handling systems industry global market size, regional shares, competitors with automated liquid handling systems market share, detailed automated liquid handling systems market segments, market trends, and opportunities, and any further data you may need to thrive in the automated liquid handling systems industry. This automated liquid handling systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Bioprocess Analyzers Market Definition And Segments

Bioprocess analyzers refer to analytical devices or systems designed to track, examine, and regulate a range of factors and procedures related to the manufacturing of biopharmaceuticals, bioprocessing, and biotechnology. These analyzers are used in various sectors to guarantee the effectiveness and quality of bioprocessing activities and allow for real-time monitoring and control of critical parameters. The main types of bioprocess analyzer products are instruments and consumables. Instruments are indispensable tools in bioprocessing, enabling the accurate measurement, analysis, control, and optimization of bioprocesses to achieve desired outcomes in terms of product yield, quality, and efficiency. These are used for various applications, such as antibiotics, recombinant proteins, biosimilars, and others, by several end-users, including biopharmaceutical companies, contract manufacturing organizations, contract research organizations, and others. The bioprocess analyzers market covered in this report is segmented – 1) By Product: Instruments, Consumables 2) By Application: Antibiotics, Recombinant Proteins, Biosimilars, Other Applications 3) By End-User: Biopharmaceutical Companies, Contract Manufacturing Organizations, Contract Research Organizations, Other End Users The bioprocess analyzers market size has grown rapidly in recent years. It will grow from $1.80 billion in 2023 to $1.99 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to demand for personalized medicine, and increasing complexity of bioprocesses The bioprocess analyzers market size is expected to see rapid growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to rise of biosimilar and bio better products, expansion of bioprocessing industries, and increased investment in research and development. Major trends in the forecast period include expansion of real-time monitoring, integration of advanced sensors, and focus on automation and connectivity.

Impact Of Rising Demand For Biopharmaceuticals On The Bioprocess Analyzers Market

The rise in demand for biopharmaceuticals is expected to propel the growth of the bioprocess analyzer market going forward. Biopharmaceuticals refers to pharmaceuticals made from biological sources, such as living things or their parts. The biopharmaceutical industry is on the rise due to creative research and development efforts that result in the creation of novel biologics and biosimilars. Bioprocess analyzers are used to monitor various parameters during the production of biopharmaceuticals, such as cell growth, protein expression, and product purity. For instance, in January 2024, according to IQVIA, a US-based provider of biopharmaceutical development services, the spending on global biotech is expected to exceed $892 billion by 2028. Furthermore, in April 2022, according to the National Library of Medicine, a US-based medical library, pharmaceutical spending in the United States increased by 7.7% in 2021 compared to the previous year, reaching a total of $576.9 billion. Therefore, the rise in demand for biopharmaceuticals is driving the growth of the bioprocess analyzer systems market. Major companies operating in the bioprocess analyzers market are Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Thermo Fisher Scientific, MilliporeSigma, Sartorius AG, Beckman Coulter Inc., Waters Corporation, Bio-Rad Laboratories, Bruker Corporation, Agilent Technologies, GE Healthcare, Pall Corporation, Eppendorf AG, HORIBA Ltd., Promega Corporation, Nova Biomedical, Hamilton Company, Macherey-Nagel GmbH & Co. KG, BioTek Instruments, Zymo Research Corporation, Gilson Inc., Metrohm AG, Biochrom Ltd., PerkinElmer Inc.

Advancements In Real-Time Monitoring Platforms For Bioprocess Analyzers

The major companies operating in bioprocess analyzers are focusing on developing advanced solutions, such as optical in-line analyzers, to gain a competitive edge in the market. Optical in-line analyzers refer to instruments that utilize optical technology to provide real-time monitoring and analysis of critical parameters in bioprocessing applications. For instance, in September 2023, 908 Devices Inc., a US-based chemical and biochemical analysis company, launched MAVERICK, an advanced optical in-line analyzer that provides real-time monitoring and control of essential factors such as glucose, lactate, and total biomass in mammalian cell cultures. Biopharmaceutical experts can utilize the device's comprehensive process fingerprint data to fine-tune large-scale bioprocesses. Its user-friendly design simplifies tasks for scientists and engineers, accelerating the development of cell culture media and the creation of effective feeding and control plans. It uses Raman spectroscopy to measure various important process parameters in real time, including glucose, lactate, and biomass, in bioreactors. Maverick is intended to improve process comprehension, optimize performance, and ensure batch-to-batch reproducibility in cell culture automation for biologic production with the CHO (Chinese hamster ovary) or HEK293 (human embryonic kidney 293) mammalian cell lines and multiple medium types.

908 Devices Expands Bioanalytics Platform With TRACE Analytics Acquisition

In September 2022, 908 Devices, a US-based chemical and biochemical analysis company, acquired TRACE Analytics for $15.3 million. The deal will help 908 Devices strengthen its bioanalytics platform by enabling them to take a measurable step forward to build a connected and comprehensive bioanalytics platform. TRACE Analytics is a US-based manufacturer of bioprocess analyzers and supplier of online analytical technologies used in bioprocess research, development, and production. North America was the largest region in the bioprocess analyzers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess analyzers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The bioprocess analyzers market consists of sales of biosensors, spectroscopic sensors, spectrophotometers, and biochemical analyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The bioprocess analyzers market research report is one of a series of new reports from The Business Research Company that provides bioprocess analyzers market statistics, including bioprocess analyzers industry global market size, regional shares, competitors with a bioprocess analyzers market share, detailed bioprocess analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocess analyzers industry. This bioprocess analyzers market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cell Culture Media Market Definition And Segments

Cell culture media refer to nutrient-rich solutions designed to support the growth, maintenance, and proliferation of cells outside of their natural environment. They typically contain a balanced mixture of amino acids, vitamins, minerals, sugars, and growth factors tailored to specific cell types. Media composition can vary widely depending on the cell's requirements and experimental objectives. The main types of cell culture media are liquid media, semi-solid media, and solid media. Liquid media refers to any fluid-based substance or solution used in manufacturing, research, or other operational activities. The different products of cell culture media are serum-free media, classical media, stem cell culture media, specialty media, chemically defined media, and others, which are used in several applications including biopharmaceutical production, diagnostics, drug screening and development, tissue engineering, and regenerative medicine, among others. It is used by various end users, such as the biotechnology and pharmaceutical industries, academic institutes, research laboratories, and others. The cell culture media market covered in this report is segmented – 1) By Type: Liquid Media, Semi-solid And Solid Media 2) By Product: Serum Free Media, Classical Media, Stem Cell Culture Media, Specialty Media, Chemically Defined Media, Other Cell Culture Media 3) By Application: Biopharmaceutical Production, Diagnostics, Drug Screening And Development, Tissue Engineering And Regenerative Medicine, Other Applications 4) By End User: Biotechnology And Pharmaceutical Industry, Academic Institute, Research Laboratory, Other End Users The cell culture media market size has grown rapidly in recent years. It will grow from $4.84 billion in 2023 to $5.46 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to growing research and development (R&D) activities, rising prevalence of chronic diseases, expansion of the biopharmaceutical industry, supportive government initiatives and funding, and growing demand for regenerative medicine and stem cell therapies. The cell culture media market size is expected to see rapid growth in the next few years. It will grow to $8.91 billion in 2028 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to an increasing focus on personalized medicine, a growing pipeline of biopharmaceutical products, expansion of stem cell research, increasing adoption of organ-on-a-chip technology for drug testing and toxicity screening, growing healthcare infrastructure, rising investments in life sciences research, and expanding biopharmaceutical manufacturing capabilities. Major trends in the forecast period include technological advancements in biotechnology, the emergence of cell and gene therapies, the adoption of organ-on-a-chip technology for drug testing and toxicity screening, the adoption of animal-free and chemically-defined cell culture media formulations, integration of advanced cell culture systems, microfluidics, and bioreactor technologies.

Rising Pharmaceutical Drug Manufacturing Fuels Growth In The Cell Culture Media Market

The increase in the manufacturing of pharmaceutical drugs is expected to propel the cell culture media market going forward. Pharmaceutical drugs refer to medications or substances used for the prevention, treatment, or diagnosis of medical conditions in humans or animals. The surge in pharmaceutical drug manufacturing can be attributed to the increased prevalence of chronic and infectious diseases and the growing aging population, which necessitates a higher demand for medications to manage age-related conditions and ailments. Cell culture media provide the essential nutrients and environment for the growth and maintenance of cells used in pharmaceutical drug manufacturing, ensuring optimal cell growth and the production of desired therapeutic proteins or molecules. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based European trade association representing the pharmaceutical industry, the total bio-pharmaceutical production in Europe accounted for $384,200 million (€340,000 million) in 2022, an increase of approximately 4.95% from $366,267 million (€323,950 million) in 2021. Therefore, the increase in the manufacturing of pharmaceutical drugs is driving the growth of the cell culture media market. Major companies operating in the cell culture media market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Corning Incorporated, Lonza Group AG, Sartorius AG, CYTIVA Lifesciences, Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec, Takara Bio, MP Biomedicals, FUJIFILM Irvine Scientific Inc., Promocell Inc., InSphero AG, PeproTech Inc., HiMedia Laboratories Pvt. Ltd., Elabscience Biotechnology Inc., Capricorn Scientific GmbH, CAISSON Laboratories Inc., Cell Biologics Inc., Nucleus Biologics LLC

Advancements In Cell Culture Media For Enhanced Biopharmaceutical Manufacturing

Major companies operating in the cell culture media market are focusing on developing innovative culture cell media, such as chemically defined and animal-component-free formulations, to gain a competitive edge in the market. Chemically defined and animal-component-free formulations aim to optimize cell growth and protein production, ultimately improving the scalability and efficiency of biopharmaceutical manufacturing processes. For instance, in July 2023, Lonza Group Ltd., a Switzerland-based healthcare company, launched TheraPRO CHO Media System, an innovative cell culture platform designed to enhance productivity and quality in therapeutic protein manufacture. This new system is tailored to optimize therapeutic monoclonal antibody production and features a chemically defined, animal-component-free, two-part production process, simplifying media preparation and ensuring scalability.

ANGUS Chemical Company Acquires Expression Systems LLC To Expand Presence In The Life Sciences Sector

In November 2022, ANGUS Chemical Company, a US-based company that produces specialty additive chemicals, acquired Expression Systems LLC for an undisclosed amount. The acquisition further strengthens ANGUS' ability to deliver value through the consistent, high-quality ingredients and services essential to all phases of bioprocessing, from early-stage biologics development to full-scale commercial production. Expression Systems LLC is a US-based manufacturer of cell culture media and related products and services. North America was the largest region in the cell culture media market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell culture media market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell culture media market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The cell culture media market consists of sales of co-culture media, conditioned media, and serum substitute media. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell culture media market research report is one of a series of new reports from The Business Research Company that provides cell culture media market statistics, including cell culture media industry global market size, regional shares, competitors with a cell culture media market share, detailed cell culture media market segments, market trends and opportunities, and any further data you may need to thrive in the cell culture media industry. This cell culture media market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Small Molecule Injectable Drugs Market Definition And Segments

Small molecule injectable drugs are pharmaceutical substances that are small in size and have a low molecular weight. These medications are often provided via injection, either intravenously, intramuscularly, or subcutaneously, to achieve systemic distribution throughout the body. The main types of drug classes in small-molecule injectable drugs are small-molecule antibiotics, analgesics, chemotherapy, antivirals, anticoagulants, skeletal muscle relaxants, anticonvulsants, and others. Small-molecule antibiotics are antibacterial medicines with a low molecular weight and simple chemical structure. The various indications include pain management, oncology, infectious diseases, cardiovascular diseases, CNS diseases, and others. The various delivery types include IV sets, intravenous injections, infusion pumps, intramuscular injections, and subcutaneous injections that are used by various end-users such as hospitals, ambulatory clinics, outpatient facilities, infusion therapy centers, home care, and others. The small molecule injectable drugs market covered in this report is segmented – 1) By Drug Class: Small Molecule Antibiotics, Analgesics, Chemotherapy, Antivirals, Anticoagulant, Skeletal Muscle Relaxants, Anticonvulsants, Other Drug Class 2) By Indication: Pain Management, Oncology, Infectious Diseases, Cardiovascular Diseases, CNS Diseases, Other Indications 3) By Mode of Delivery: IV Set, Intravenous Injection, Infusion Pump, Intramuscular Injection, Subcutaneous Injection 4) By End User: Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, Home Care, Other End Users The small molecule injectable drugs market size has grown rapidly in recent years. It will grow from $195.14 billion in 2023 to $220.85 billion in 2024 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to rising chronic diseases, aging population, government initiatives, increasing healthcare expenditure, improved manufacturing processes. The small molecule injectable drugs market size is expected to see rapid growth in the next few years. It will grow to $355.14 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to personalized healthcare, digital health integration, supply chain optimization, real-world evidence utilization, shift towards outpatient care. Major trends in the forecast period include advancements in drug delivery systems, technological advancements, focus on research and development, innovation in injectable therapies, fast-track approvals of new drug formulation.

Rising Chronic Diseases Fuel Growth In The Small-Molecule Injectable Drug Market

The rising chronic diseases are expected to propel the growth of the small-molecule injectable drug market going forward. Chronic diseases are conditions characterized by long-term persistence and typically slow progression. Chronic diseases are on the rise due to a combination of factors, including sedentary lifestyles, unhealthy dietary habits, tobacco use, and increasing levels of stress. These lifestyle choices contribute to the development of conditions such as obesity, diabetes, cardiovascular diseases, and certain types of cancer. Small-molecule injectable drugs play a valuable role in managing chronic diseases by offering targeted therapy, improved compliance, disease modification, combination therapy options, and opportunities for therapeutic monitoring. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, rising chronic diseases drive the small-molecule injectable drug market. Major companies operating in the small molecule injectable drugs market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals plc, BioCryst Pharmaceuticals Inc., Mylan N.V.

Small Molecule Injectable Drugs In Precision Medicine

Companies in the small-molecule injectable drug market are focused on developing new technologies such as a new microparticle technology, to enhance the solubility of active pharmaceutical ingredients in oral drug products. Microparticle technology refers to the design, production, and application of particles at the microscale level, typically ranging from nanometers to micrometers in size. These particles can be engineered from various materials, including polymers, metals, ceramics, and composites. For instance, in March 2022, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRATEC SoluFlow, a new microparticle technology designed to enhance the solubility of active pharmaceutical ingredients in oral drug products. This innovative emulsion-based process technology addresses solubility challenges that traditional manufacturing methods struggle to overcome, particularly for new small-molecule therapeutics where over 70% of compounds are insoluble. EUDRATEC SoluFlow enables the development of new oral therapeutics in various areas, such as cancer, cardiovascular diseases, infectious diseases, and diabetes, by transforming poorly soluble drugs into free-flowing powders of amorphous solid dispersions (ASD).

Ardena's Acquisition Of Idifarma On The Pharmaceutical Landscape

In September 2021, Ardena, a Belgium-based pharmaceutical company, acquired Idifarma from Suanfarma for an undisclosed amount. This acquisition would enhance Ardena's goal of becoming a single-source contractor offering integrated services to meet chemical, pharmaceutical, and bio-analytical needs throughout the clinical supply chain. Idifarma is a Spain-based pharmaceutical contract development and manufacturing company that offers small-molecule injectable drugs. North America was the largest region in the small molecule injectable drugs market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule injectable drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small molecule injectable drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The small molecule injectable drugs market consists of sales of antineoplastic agents, hormones, and vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The small molecule injectable drugs market research report is one of a series of new reports from The Business Research Company that provides small molecule injectable drugs market statistics, including small molecule injectable drugs industry global market size, regional shares, competitors with a small molecule injectable drugs market share, detailed small molecule injectable drugs market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule injectable drugs industry. This small-molecule injectable drug market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry. 

Cold Chain Temperature Monitoring Market Definition And Segments

Cold chain temperature monitoring refers to the process of continuously monitoring and tracking the temperature of perishable goods, pharmaceuticals, vaccines, and other temperature-sensitive products as they are transported or stored within a controlled environment. It utilizes various technologies, including sensors and data loggers, to consistently oversee the temperature conditions of perishable items to guarantee that these products are stored and transported within ideal temperature parameters, thereby preserving their quality, safety, and overall integrity. The main types of hardware used in cold chain temperature monitoring include conventional temperature loggers, real-time monitoring devices, resistance temperature detectors, temperature indicators, and others. Conventional temperature loggers refer to standard temperature monitoring devices used in cold chain logistics and monitoring to track and record temperature data at set intervals, ensuring the safe transportation and storage of perishable items like food and pharmaceuticals. The software types include on-premise and cloud-based for end users such as fish, meat, and seafood, processed food, pharmaceuticals, bakeries and confectionaries, fruits and vegetables, dairy products, and other end users. The cold chain temperature monitoring market covered in this report is segmented – 1) By Hardware: Conventional Temperature Loggers, Real Time Monitoring Devices, Resistance Temperature Detectors, Temperature Indicators, Other Hardware 2) By Software: On Premise, Cloud Based 3) By End User: Fish, Meat And Seafood, Processed Food, Pharmaceuticals, Bakery And Confectionaries, Fruits And Vegetables, Dairy Products, Other End Users The cold chain temperature monitoring market size has grown rapidly in recent years. It will grow from $7.52 billion in 2023 to $8.79 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to increased global trade, rising demand for pharmaceutical products, importance of maintaining product quality, growing availability of cold chain logistics, focus on predictive maintenance. The cold chain temperature monitoring market size is expected to see rapid growth in the next few years. It will grow to $16.64 billion in 2028 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to integration of emerging technologies by key players, expansion and enhancement of product portfolios, adoption of innovative temperature monitoring solutions, increasing demand for cold chain tracking in developing countries, focus on automation and cold storage technologies. Major trends in the forecast period include increased use of sensors and data loggers, expansion of software solutions for cold chain monitoring, emphasis on security and safety in monitoring systems, Preference for on premise software solutions, focus on improving operational effectiveness.

E-Commerce Expansion Fuels Demand For Cold Chain Temperature Monitoring Solutions

The expansion of e-commerce is expected to propel the growth of the cold chain temperature monitoring market going forward. E-commerce refers to the buying and selling goods and services over an electronic network, primarily the internet. E-commerce expands due to its convenience, technological advancements, and accelerated adoption during the COVID-19 pandemic, enabling businesses to reach a global market while transforming supply chain logistics. Cold chain temperature monitoring systems provide real-time visibility and control over temperature-sensitive products, enabling e-commerce companies to maintain product quality, meet customer expectations, and demonstrate regulatory compliance. For instance, in November 2023, according to the United States Census Bureau, a US-based government agency, total e-commerce sales in the USA for 2023 were $1,118.7 billion, an increase of 7.6% from 2022. Therefore, the expansion of e-commerce is driving the growth of the cold chain temperature monitoring market. Major companies operating in the cold chain temperature monitoring market are Zebra Technologies Corporation, Cryoport Inc., Cold Chain Technologies, Controlant, Sensitech Inc., OMEGA Engineering inc., Luna, Elitech, MOBIQU, Thermo Electric Company Inc., DeltaTrak Inc., Berlinger & Co. AG, Insignia Technologies, Softbox, CargoSense, PakSense, Elpro-Buchs AG, CubeWorks, Infratab Inc., Kedeon, CWD Limited, ORBCOMM, Roambee Corporation, iMatrix Cloud, AeroSafe Global

Technology Solutions Driving Efficiency In Cold Chain Temperature Monitoring

Major companies operating in the cold chain temperature monitoring market are developing innovative temperature trackers, such as CubiSens XT1, to enhance real-time monitoring and ensure the integrity of temperature-sensitive products throughout the supply chain. CubiSens XT1 is a tracker that utilizes various sensor technologies to measure and record temperature conditions at different product transportation and storage stages. For instance, in September 2022, CubeWorks, a US-based technology company, launched CubiSens XT1. CubiSens XT1 aims to provide a comprehensive solution for monitoring and optimizing agricultural processes. It integrates various sensors and technologies to gather data on environmental conditions, crop health, soil moisture, and other relevant factors. The ultimate goal is to help farmers make informed decisions, increase crop yields, optimize resource usage, and improve overall efficiency and sustainability in agriculture.

Azenta Enhances Cold Chain Capabilities With Acquisition Of B Medical Systems SA

In October 2022, Azenta Inc., a US-based biotech company, acquired B Medical Systems SA for an undisclosed amount. This strategic acquisition strengthens Azenta's cold chain capabilities by integrating differentiated solutions for the dependable and traceable transport of temperature-sensitive specimens. SA is a Luxembourg-based medical refrigeration manufacturer offering cold chain temperature monitoring solutions. North America was the largest region in the cold chain temperature monitoring market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cold chain temperature monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cold chain temperature monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The cold chain temperature monitoring market consists of revenues earned by entities by providing services such as consulting and advisory services, temperature mapping and validation, data analytics and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The cold chain temperature monitoring market also includes sales of temperature labels and indicators, wireless temperature sensors, temperature monitoring systems, temperature probes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cold chain temperature monitoring research report is one of a series of new reports from The Business Research Company that provides cold chain temperature monitoring market statistics, including the cold chain temperature monitoring industry's global market size, regional shares, competitors with a cold chain temperature monitoring market share, detailed cold chain temperature monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the cold chain temperature monitoring industry. This cold chain temperature monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Lentiviral Vector Market Definition And Segments

A lentiviral vector refers to a type of viral vector derived from lentiviruses, a subgroup of retroviruses known for their ability to integrate genetic material into the DNA of the host cell's genome. These vectors are commonly used in molecular biology and gene therapy applications to deliver genetic material into target cells for various purposes, including gene expression, gene silencing, or genetic modification. The main types of products in the lentiviral vector are kits, reagents and consumables. Lentiviral vector kits encompass a comprehensive set of tools and components required for the generation and manipulation of lentiviral vectors. It can be used for various indications, including cancer, genetic disorders, infectious diseases, veterinary diseases, and others, and it includes various users such as biotechnology companies, pharmaceutical companies, contract research organizations (CROs), and academic and research institutes. The lentiviral vector market covered in this report is segmented – 1) By Product Type: Kits, Reagents And Consumables 2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications 3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes The lentiviral vector market size has grown rapidly in recent years. It will grow from $12.50 billion in 2023 to $14.37 billion in 2024 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to prevalence of genetic disorders, gene delivery demand, biotech and pharma expansion, clinical trial investment, regulatory approvals. The lentiviral vector market size is expected to see rapid growth in the next few years. It will grow to $25.50 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to personalized medicine growth, gene editing innovations, rare disease therapy demand, lentiviral vector adoption, genomic medicine funding, manufacturing scalability focus. Major trends in the forecast period include expansion of research and development, integration in CAR-T cell therapy, development of next-generation vectors, adoption in vaccine development, development of production technologies.

Lentiviral Vectors Market Driven By Rising Prevalence Of Chronic Diseases

The increasing prevalence of chronic diseases is expected to propel the lentiviral vectors market going forward. Chronic diseases refer to long-term medical conditions that typically progress slowly over time and often persist for years or even a lifetime. The prevalence of chronic diseases is increasing due to aging populations, unhealthy lifestyles, urbanization, and environmental factors. Lentiviral vectors offer versatile and efficient tools for developing vaccines and treatment strategies for chronic diseases, addressing unmet medical needs, and improving patient outcomes. For instance, in January 2023, according to the report published by the National Library of Medicine, the US-based medical library, It is expected that there will be around 142.66 million people with at least one chronic illness by 2050, a 99.5% rise from 71.522 million in 2020. Therefore, the increasing prevalence of chronic diseases is driving the growth of the lentiviral vectors market. Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

Technological Advancements In Lentiviral Vector Production For Immuno-Oncology Therapies

Major companies operating in the lentiviral vectors market are focusing on developing LV vector production platforms, such as LentiSure, to enhance the efficiency and robustness of producing lentivirus vectors for cell-based immuno-oncology therapies. LentiSure is the LV vector production platform producing lentiviral vectors used in cell-based immuno-oncology therapies. It is designed to enhance efficiency and robustness in generating vectors. For instance, in May 2023, Yposkesi sk pharmteco, a France-based manufacturer of viral vectors, launched LentiSure, an advanced platform designed to enhance the production of lentiviral (LV) vectors, aiming to improve the resilience and efficiency of lentivirus production. This platform addresses the growing demand for robust and economically scalable viral-vector manufacturing technologies in cell and gene therapies. It offers consistent product quality with average titers at cell culture harvest at 10e7 IG/mL bioreactor volume, ensuring higher productivity and success for cell therapy developers.

Charles River Laboratories Enhances Gene Therapy Capabilities With Vigene Biosciences Acquisition

In June 2021, Charles River Laboratories, a US-based pharmaceutical company, acquired Vigene Biosciences for $292.5 million. Through this acquisition, Charles River aimed to enhance its gene therapy capabilities, particularly in the high-growth cell and gene therapy CDMO sectors for viral vectors and plasmid DNA, to better meet the clients' evolving scientific needs. Vigene Biosciences is a US-based viral vector-based gene delivery service and product provider. North America was the largest region in the lentiviral vector market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lentiviral vector market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The lentiviral vector market consists of sales of 3rd generation lentiviral vectors, Lenti-ORF clones, and lentiviral particles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The lentiviral vector market research report is one of a series of new reports from The Business Research Company that provides lentiviral vector market statistics, including lentiviral vector industry global market size, regional shares, competitors with a lentiviral vector market share, detailed lentiviral vector market segments, market trends and opportunities, and any further data you may need to thrive in the lentiviral vector industry. This lentiviral vector market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.